Medical Oncology

, 30:538 | Cite as

Detection and quantification of CSF malignant cells by the CellSearch® technology in patients with melanoma leptomeningeal metastasis

  • Emilie Le Rhun
  • Qian Tu
  • Marcelo De Carvalho Bittencourt
  • Isabelle Farre
  • Laurent Mortier
  • Huili Cai
  • Chantal Kohler
  • Gilbert C. Faure
Short Communication


Melanoma is the most frequent solid tumor associated with leptomeningeal metastasis (LM). The usual diagnostic tools, that is, cytomorphological assessment of cerebro-spinal fluid (CSF) and gadolinium-enhanced MRI of the entire neuraxis both lack effectiveness. The CellSearch® Veridex technology for the detection of circulating tumor cells (CTC) in blood was designed for the follow-up and prognosis of breast, prostate, colorectal, and lung cancer, which express EpCAM markers. We have previously adapted this technology to detect malignant cells in the CSF of breast cancer LM. Our objective here was to check if this technology would also allow the detection and the enumeration of CTC in the CSF of melanoma patients presenting with LM although melanoma does not express EpCAM markers. On the occasion of the intrathecal treatment of LM in 2 melanoma patients, 5 mL of CSF and 7.5 mL of blood were collected on CellSave® Preservative Tubes and analyzed within 3 days after CSF sampling using a melanoma-dedicated kit. The CellSearch® Veridex technology was then adapted to direct enrichment, enumeration, and visualization of melanoma cells in the CSF. CD146+, HMW-MAA+, CD34−, and CD45− cells with typical morphology could be observed and enumerated sequentially with reproducible results, corresponding to CSF melanoma cells (CSFMC). In contrast to the current gold standard cytomorphological analysis, this new approach allowed a precise quantification of CSFMC in all samples concomitantly analyzed. This methodology, established on a limited volume of sample and allowing delayed processing, could prove of great interest in the diagnosis and follow-up of melanoma patients with LM.


Leptomeningeal metastasis Neoplastic meningitis CellSearch® technology Immunomagnetic enrichment CSF cytology Melanoma 



This work has been supported by EA RHEM4369, Université de Lorraine.

QT and HC are supported by Chinese Scientific Council.

This work was not funded by the manufacturer or distributor of Cellsearch technology®.

Conflict of interest

None declared.


  1. 1.
    Moseley RP, Davies AG, Bourne SP, Popham C, Carrel S, Monro P, et al. Neoplastic meningitis in malignant melanoma: diagnosis with monoclonal antibodies. J Neurol Neurosurg Psychiatry. 1989;52:881–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, Bonneterre J, Mortier L, Le Rhun E. Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo. 2012;26(6):1079–86.PubMedGoogle Scholar
  4. 4.
    Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008;10:1010–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Carlino MS, Fogarty GB, Long GV. Treatment of melanoma brain metastases: a new paradigm. Cancer J. 2012;18(2):208–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman RB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Chamberlain MC. Leptomeningeal metastasis. Curr Opin Neurol. 2009;22:665–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Koyanagi K, O’Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010;16(8):2402–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119(10):3172–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012;255(2):357–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011;38(3):755–60.PubMedGoogle Scholar
  13. 13.
    Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, et al. Circulating tumor cells in melanoma patients. PLoS ONE. 2012;7(7):e41052.PubMedCrossRefGoogle Scholar
  14. 14.
    Weston CL, Glantz MJ, Connor JR. Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS. 2011;8(1):14.PubMedCrossRefGoogle Scholar
  15. 15.
    Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.PubMedCrossRefGoogle Scholar
  16. 16.
    Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752–60.PubMedGoogle Scholar
  17. 17.
    Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt MD, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12(1):21.PubMedCrossRefGoogle Scholar
  18. 18.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med. 2004;351(8):781–91.PubMedCrossRefGoogle Scholar
  19. 19.
    De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;15(19):6302–9.CrossRefGoogle Scholar
  20. 20.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbah KD, Gabrai NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Emilie Le Rhun
    • 1
    • 2
  • Qian Tu
    • 3
    • 4
  • Marcelo De Carvalho Bittencourt
    • 3
    • 4
  • Isabelle Farre
    • 5
  • Laurent Mortier
    • 6
    • 7
  • Huili Cai
    • 3
    • 4
  • Chantal Kohler
    • 3
    • 4
  • Gilbert C. Faure
    • 3
    • 4
  1. 1.Neurology, Breast Unit, Department of Medical OncologyOscar Lambret CenterLille CedexFrance
  2. 2.Neuro-oncology, Hopital Roger SalengroCentre Hospitalier et UniversitaireLille CedexFrance
  3. 3.CHU Nancy, Nancytomique, Laboratoire d’Immunologie, Pôle LaboratoiresVandoeuvre lès NancyFrance
  4. 4.Faculté de MédecineUniversité Henri Poincaré, EA4369 RHEMVandoeuvre lès NancyFrance
  5. 5.Department of PathologyOscar Lambret CenterLille CedexFrance
  6. 6.Department of Dermatology, Huriez HospitalRegional and University HospitalLilleFrance
  7. 7.University of Lille North of FranceLilleFrance

Personalised recommendations